Skip to main navigation Skip to search Skip to main content

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

  • SAPPHIRE Investigators
  • IRCCS Istituto Europeo di Oncologia - Milano
  • Erasmus University Rotterdam
  • Florida Cancer Specialists and Research Institute – South Region (SCRI)
  • Netherlands Cancer Institute
  • Hospital Regional Universitario Carlos Haya
  • Sarah Cannon Research Institute
  • Paoli-Institut Calmettes
  • University of California at Los Angeles
  • Ohio State University
  • Université Paris-Sud
  • German Center for Lung Research
  • Royal Marsden NHS Foundation Trust
  • Yale University
  • Emory University
  • Mirati Therapeutics
  • University of Lausanne

Research output: Contribution to journal › Article › peer-review

91 Scopus citations

Fingerprint

Dive into the research topics of 'SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science